A Phase I Study to Evaluate the Safety and Tolerability and Pharmacokinetic/Pharmacodynamics of MK-8242 in Patients With Advanced Solid Tumors

Inclusion Criteria

Inclusion criteria:

- Histologically confirmed advanced solid tumor for which there are no effective
standard therapy options

- Willing to provide tumor tissue for p53 wild type gene analysis Eastern Cooperative
Oncology Group (ECOG) performance status of ≤1

- Adequate organ function

- Female participants and male participants and their partners who are of childbearing
potential must agree to abstain from sexual intercourse or to use an acceptable
method of contraception during the study and for 90 days following the last dose of
study therapy

- At least one measurable lesion

- In Part 2, participants with liposarcoma must have a confirmed well-differentiated or
de-differentiated histology

Exclusion criteria:

- Known treated or untreated leptomeningeal metastases, or metastatic central nervous
system disease

- History of recent myocardial infarction (within the past year); or with unstable or
uncontrolled angina, New York Heart Association (NYHA) Class III or IV congestive
heart failure, uncontrolled hypertension, clinically significant cardiac dysrhythmia
or clinically significant electrocardiogram (ECG) abnormality

- Uncontrolled active infection on optimal systemic treatment

- Clinically significant hepatitis or hepatitis C antibody positive, hepatitis B
surface antigen positive, or human immunodeficiency virus (HIV) seropositive

- Persistent, unresolved common terminology criteria for adverse events (CTCAE v4.0)
≥Grade 2 drug-related toxicity associated with previous treatment except for alopecia

- Radiation therapy or other loco-regional therapy within 2 weeks prior to study

- Use of moderate and strong Cytochrome P450 inhibitors or inducers within 1 week prior
to study

- Chemotherapy or any investigational drug(s) within 4 weeks prior to study

- Known hypersensitivity to MK-8242 or its components

- Nursing, pregnant, or intention to become pregnant during the study

- Initiating bisphosphonate therapy or adjusting the bisphosphonate dose or regimen
within 30 days of Cycle 1 Day 1